Reported remission duration from a single stem cell infusion ranges 4–9 months in published trials. Some patients experience sustained remission beyond 12 months; others relapse by month 5. Maintenance of benefit often requires concurrent standard medical therapy (5-ASA, corticosteroids, or immunosuppressants), yet interaction between cell therapy and conventional drugs is poorly characterised. Repeat dosing protocols are not standardised. Durability compared to biologic therapy (which is dosed regularly and requires ongoing treatment) remains unclear.
Ulcerative colitis is a chronic inflammatory bowel disease affecting the colon and rectum, characterised by bloody diarrhoea, urgency, abdominal pain, and systemic complications including anaemia and extraintestinal manifestations. Modern management combines 5-aminosalicylate agents, immunosuppression, and biologic therapies; however, a significant proportion of patients experience relapsing disease or intolerance to standard drugs. Mesenchymal stem cell research in UC explores whether cell-derived immunomodulatory factors might suppress mucosal inflammation and promote tissue healing. Related approved therapies (such as an MSC product indicated for perianal Crohn's fistulae) provide mechanistic precedent, though this distinct indication remains investigational in UC.
Съм ли кандидат? → · Ulcerative Colitis: full overview → · Цена Улцерозен колит → · Cost →
Медицински преглед от редакционния екип на StemCellAtlas с Dr Polina Krasenova (Haematologist · Clinical Haematology & Integrative Oncology · 15+ yrs cell therapy) на партньорската клиника Stem Plus (София), спрямо ISSCR, FDA и EMA указания. Educational information, not medical advice; figures indicative.
GMP-сертифицирана регенеративна медицина в сърцето на ЕС — от 3 000–8 000 €, част от цените в САЩ или Германия. Персонализирани протоколи за пациенти от над 50 държави.
Безплатна медицинска оценка